tradingkey.logo

Anteris Technologies Global Corp

AVR
查看詳細走勢圖
5.320USD
+0.380+7.69%
收盤 12/22, 16:00美東報價延遲15分鐘
191.85M總市值
虧損本益比TTM

Anteris Technologies Global Corp

5.320
+0.380+7.69%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+7.69%

5天

+6.83%

1月

+51.14%

6月

+30.71%

今年開始到現在

-4.66%

1年

-4.66%

查看詳細走勢圖

操作建議

Anteris Technologies Global Corp當前公司基本面數據相對健康,增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名96/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價16.50。中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Anteris Technologies Global Corp評分

相關信息

行業排名
96 / 208
全市場排名
226 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
16.500
目標均價
+245.91%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Anteris Technologies Global Corp亮點

亮點風險
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
業績增長期
公司處於發展階段,最新年度總收入2.70M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入2.70M美元
估值合理
公司最新PE估值-2.11,處於3年歷史合理位
機構加倉
最新機構持股25.19M股,環比增加5.38%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉2.04K股

Anteris Technologies Global Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Anteris Technologies Global Corp簡介

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
公司代碼AVR
公司Anteris Technologies Global Corp
CEOPaterson (Wayne G)
網址https://anteristech.com/

常見問題

Anteris Technologies Global Corp(AVR)的當前股價是多少?

Anteris Technologies Global Corp(AVR)的當前股價是 5.320。

Anteris Technologies Global Corp 的股票代碼是什麼?

Anteris Technologies Global Corp的股票代碼是AVR。

Anteris Technologies Global Corp股票的52週最高點是多少?

Anteris Technologies Global Corp股票的52週最高點是8.790。

Anteris Technologies Global Corp股票的52週最低點是多少?

Anteris Technologies Global Corp股票的52週最低點是2.340。

Anteris Technologies Global Corp的市值是多少?

Anteris Technologies Global Corp的市值是191.85M。

Anteris Technologies Global Corp的淨利潤是多少?

Anteris Technologies Global Corp的淨利潤為-76.29M。

現在Anteris Technologies Global Corp(AVR)的股票是買入、持有還是賣出?

根據分析師評級,Anteris Technologies Global Corp(AVR)的總體評級為買入,目標價格為16.500。

Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是多少

Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是-2.341。
KeyAI